Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer look in Europe and Daiichi Sankyo is switching CEOs.
Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer look in Europe and Daiichi Sankyo is switching CEOs.
